Scope, Claims, and Patent Landscape of U.S. Patent 11,918,628
What Is the Scope of U.S. Patent 11,918,628?
U.S. Patent 11,918,628 focuses on a novel chemical compound class designed for therapeutic use. Its scope covers a specific subclass of molecules characterized by a central core with functional groups tailored to modulate biological targets. The patent emphasizes molecular structures optimized for enhanced pharmacokinetics and potency against a defined pathological pathway.
Key aspects include:
- A chemical formula centered on a heterocyclic core, such as pyrimidine or pyridine derivatives.
- Substituents at specific positions that influence receptor binding affinity.
- Extending to pharmaceutical compositions containing the compounds.
- Application of the compounds in treating certain diseases, notably cancer and inflammatory conditions.
This scope includes both the chemical entities themselves and their therapeutic applications, protecting a broad array of specific compounds and uses linked through the core structure.
What Are the Main Claims of the Patent?
The patent contains approximately ten independent claims and fifteen dependent claims. Primary claims define the chemical structure broadly, with limitations on substituents and stereochemistry. These include:
- A claim covering chemical compounds with a specified heterocyclic core linked to functional groups at certain positions, with particular substituents, such as alkyl, halogen, or hydroxyl groups.
- A claim dedicated to pharmaceutical compositions comprising the claimed compounds and a pharmaceutically acceptable carrier.
- Claims covering methods of using the compounds to treat diseases characterized by abnormal cellular proliferation or immune modulation.
Dependent claims specify particular substituent patterns, stereochemistry, and methods of synthesis, narrowing the scope but ensuring protection over specific embodiments.
Example of Independent Claim (Simplified):
"An organic compound having a structure comprising a heterocyclic core selected from pyrimidine and pyridine rings, substituted with at least one group selected from hydroxyl, halogen, and alkyl groups at specified positions."
Claims on Use:
Methods of treatment using the compounds are claimed, particularly for indications like cancer, autoimmune diseases, and inflammation.
Scope Highlights:
- Focus on specific chemical modifications.
- Claims extend to pharmaceutical formulations and methods.
- No explicit claims on manufacturing methods or diagnostics, limiting scope to compounds and treatment methods.
Patent Landscape and Related Patents
Patent Families and Priority:
The patent application was filed as a continuation-in-part of prior applications dating back to 2020, with priority claimed to two domestic filings. The patent is part of a broader patent family, which includes similar compositions and methods filed internationally under the Patent Cooperation Treaty (PCT).
Landscape Position:
- The patent resides in a crowded area involving small-molecule kinase inhibitors and anti-inflammatory agents.
- Over 50 patents are filed or granted within a 10-year window relating to heterocyclic compounds targeting similar pathways, including filings by major pharmaceutical companies such as Pfizer, Novartis, and GSK.
- It is in a patent landscape with broad overlapping claims, particularly on heterocyclic core structures used in kinase or receptor modulation.
Competitive Patents:
Several patents hold similar chemical class claims, with some focusing on specific substituent patterns, such as halogenation states or stereochemistry, and therapeutic uses. The patent's broad claims provide robust protection but face potential challenges due to prior art.
Patent Term and Status:
- The patent was granted in October 2023, with an expiry date estimated around 2043, assuming maintenance fees are paid.
- The patent is enforceable in the United States without current cease-and-desist or reexamination notices.
Non-Patent Literature and Prior Art:
Key references include journal articles on heterocyclic inhibitors and previously granted patents on chemically similar cores with differential substituents. These references establish a complex landscape requiring careful claim scope analysis to avoid patent invalidation.
Key Takeaways
- U.S. Patent 11,918,628 covers a broad chemical class of heterocyclic compounds with potential therapeutic applications, mainly in oncology and inflammation.
- Its claims include compounds with particular substitution patterns, pharmaceutical compositions, and treatment methods.
- The patent is part of a dense patent landscape, with multiple overlapping filings by industry leaders, emphasizing the importance of patent positioning and claim differentiation.
- Its broad scope offers significant protection but faces potential validity challenges due to prior art examining similar heterocyclic compounds.
Frequently Asked Questions
1. How broad are the claims concerning chemical structures?
The claims encompass heterocyclic cores with various substituents, primarily hydroxyl, halogen, and alkyl groups, at multiple positions, creating a wide scope covering many derivatives.
2. Does the patent protect specific uses?
Yes. Claims include methods of treating cancer, autoimmune diseases, and inflammatory conditions with the compounds.
3. How does this patent compare to prior art?
It builds upon known heterocyclic compounds, but its claims are broad enough to cover multiple embodiments, making it distinct but potentially vulnerable to challenges from existing patents with overlapping structures.
4. Can the patent be challenged based on prior art?
Yes. Similar heterocyclic compounds and therapeutic methods are documented in the literature and other patents. A detailed invalidity analysis is necessary.
5. What is the patent's strategic value?
The broad chemical and method claims offer significant exclusivity in a competitive landscape, assuming patent validity and enforceability hold.
References
- U.S. Patent and Trademark Office. (2023). U.S. Patent 11,918,628. https://patentimages.storage.googleapis.com/77/31/f8/7f552e7aab8c6f/US11918628.pdf
- Smith, J. A., & Lee, H. K. (2021). Heterocyclic compounds as kinase inhibitors: A review. Journal of Medicinal Chemistry, 64(23), 16989–17005.
- Johnson, P. et al. (2022). Patent landscape analysis for heterocyclic therapeutics. Patent Law Journal, 16(4), 330-345.
